Skip to main content

Showing 5 matches for the following: Inventor: "Cullen, Bryan" ×

Gene therapy for long-term treatment of GSDIa

Gene therapy for long-term treatment of GSDIa

Unmet Need Glycogen storage disease type Ia (GSDIa), or von Gierke disease, is a rare heritable metabolic disorder that impacts the liver and kidneys due to an inability to break down glycogen. An estimated 1…

Read More

Method for increasing gene expression in mammalian cells from transfected plasmids

Method for increasing gene expression in mammalian cells from transfected plasmids

Unmet Need Mammalian cell-based protein expression systems enable the production of mammalian proteins in the most native structure and activity. Thus, they have been commonly used for producing antibodies and therapeutic proteins, and more recently,…

Read More

Inactivating viral replication with CRISPR/Cas systems

Inactivating viral replication with CRISPR/Cas systems

Value Proposition Current gene therapy approaches based upon targeted DNA endoculeases, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), are based upon custom built DNA binding domains. Although gene therapy with…

Read More

Viral microRNAs expressed in cells latently infected with Herpes Simplex Virus Type 1

Viral microRNAs expressed in cells latently infected with Herpes Simplex Virus Type 1

The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs…

Read More

Selective inhibition of mammalian gene expression by endogenous production of designed micro RNAs (miRNAs)

Selective inhibition of mammalian gene expression by endogenous production of designed micro RNAs (miRNAs)

This patent pending technology uses artificial miRNAs, transcribed from a plasmid or viral vector, to specifically and stably eliminate protein expression for individual gene targets both in vitro and in vivo. The unique temporal and/or…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us